163 related articles for article (PubMed ID: 37058173)
1. Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphoma.
Lueza B; Aupérin A; Rigaud C; Gross TG; Pillon M; Delgado RF; Uyttebroeck A; Amos Burke GA; Zsíros J; Csóka M; Simonin M; Patte C; Minard-Colin V; Bonastre J
Eur J Health Econ; 2024 Mar; 25(2):307-317. PubMed ID: 37058173
[TBL] [Abstract][Full Text] [Related]
2. Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial.
Alexander S; Aupérin A; Bomken S; Csóka M; Kazanowska B; Chiang AK; Andres M; Uyttebroeck A; Burke GAA; Zsiros J; Pillon M; Bollard CM; Mussolin L; Verdu-Amoros J; Neven B; Barkauskas DA; Wheatley K; Patte C; Gross TG; Minard-Colin V; ;
Lancet Haematol; 2023 Jun; 10(6):e445-e457. PubMed ID: 37094596
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.
Minard-Colin V; Aupérin A; Pillon M; Burke GAA; Barkauskas DA; Wheatley K; Delgado RF; Alexander S; Uyttebroeck A; Bollard CM; Zsiros J; Csoka M; Kazanowska B; Chiang AK; Miles RR; Wotherspoon A; Adamson PC; Vassal G; Patte C; Gross TG; ;
N Engl J Med; 2020 Jun; 382(23):2207-2219. PubMed ID: 32492302
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of rituximab in children and adolescents with mature B-cell non-Hodgkin's lymphoma: a Meta analysis].
Li BY; Han YH; Yin CY; DU WC; Li YF; Wang YC
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jan; 25(1):51-59. PubMed ID: 36655664
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
7. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
8. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
Hill G; Barron R; Fust K; Skornicki ME; Taylor DC; Weinstein MC; Lyman GH
J Med Econ; 2014 Jan; 17(1):32-42. PubMed ID: 24028444
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
Dewilde S; Woods B; Castaigne JG; Parker C; Dunlop W
J Med Econ; 2014 Feb; 17(2):111-24. PubMed ID: 24308372
[TBL] [Abstract][Full Text] [Related]
11. Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
Mori T; Osumi T; Kada A; Ohki K; Koga Y; Fukano R; Fujita N; Mitsui T; Mori T; Saito AM; Nakazawa A; Kobayashi R; Sekimizu M
Eur J Haematol; 2024 Apr; 112(4):585-593. PubMed ID: 38112205
[TBL] [Abstract][Full Text] [Related]
12. [Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].
Braga P; Carvalho S; Gomes M; Guerra L; Lúcio P; Marques H; Negreiro F; Pereira C; Silva C; Teixeira A
Acta Med Port; 2010; 23(6):1025-34. PubMed ID: 21627880
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.
Nam J; Milenkovski R; Yunger S; Geirnaert M; Paulson K; Seftel M
J Med Econ; 2018 Jan; 21(1):47-59. PubMed ID: 28837377
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma.
Fagnoni P; Milpied N; Limat S; Deconinck E; Nerich V; Foussard C; Colombat P; Harousseau JL; Woronoff-Lemsi MC;
Pharmacoeconomics; 2009; 27(1):55-68. PubMed ID: 19178124
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma.
Wirt DP; Giles FJ; Oken MM; Solal-Celigny P; Beck JR
Leuk Lymphoma; 2001 Feb; 40(5-6):565-79. PubMed ID: 11426529
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of rituximab for non-Hodgkin's lymphoma: a systematic review.
Auweiler PW; Müller D; Stock S; Gerber A
Pharmacoeconomics; 2012 Jul; 30(7):537-49. PubMed ID: 22612993
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis for
Huang X; Huang X; Lin S; Luo S; Dong L; Lin D; Huang Y; Xie C; Nian D; Xu X; Weng X
BMJ Open; 2023 Mar; 13(3):e068943. PubMed ID: 36972963
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK.
Ray JA; Carr E; Lewis G; Marcus R
Value Health; 2010; 13(4):346-57. PubMed ID: 20070643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
